Financial Implications Of Mergers

𝐌&𝐀 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬: 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝐢𝐧 𝐭𝐡𝐞 300-700 𝐄𝐦𝐩𝐥𝐨𝐲𝐞𝐞 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐙𝐨𝐧𝐞 In last year, I have observed the following challenges of acquiring companies sized 300-700 people, particularly those founder-owned. Key issues include: - Skyrocketing Valuations: Multiples exceeding 15x adjusted EBITDA are commonplace due to private equity competition. - Inflated Financials: EBIT can be cosmeticized by 3-5 points, obscuring true profitability. - Minimal Synergies: Limited cost savings often exist within this size range. 𝐂𝐚𝐬𝐞 𝐒𝐭𝐮𝐝𝐲: 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐀𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 For instance, i was involved in acquiring a digital engineering company to expand our capabilities. Here are the challenges i faced: - Inflated Prices: The growing demand for specialized software engineering skills drives up valuations across the sector. - Non-Recurring Expenses: The target may have one-time R&D investments in the year just before a potential sale. They could classify these as non-recurring expenses, artificially inflating EBITDA. Amortization Mismatch: The target amortizes the cost of key software licenses over a longer period than the industry standard to increase short-term profit appearances. Valuation & Negotiation: The target was a 60-employee firm with expertise in embedded systems design, reporting an EBITDA of $2 million. Initial due diligence reveals: - $300,000 in R&D projects classified as one-time expenses. - A $150,000 software license amortized over 5 years, while the industry standard is 3 years. - Potential client dispute with a potential for $100,000 in damages. Adjusted EBITDA: When these items are factored in, a more realistic EBITDA is closer to $1.45 million ($2 million - $300,000 -$150,000 - $100,000). Traditional acquisition multiples for the sector are around 8x EBITDA. The investment banker demanded a 10x multiple based on unadjusted figures ($20 million valuation). I gave a counteroffer with a valuation based on the adjusted EBITDA of $1.45 million and an 8x multiple, proposing an acquisition price of $11.6 million. Ultimately, we had to negotiate on the midpoint. 𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲: Scrutinize EBITDA adjustments – they're the #1 tool for valuation manipulation. Failure to do so can lead to drastic overpayment. Are you seeing these in recent M&A deals? Question for the Community: Are you witnessing similar trends in recent M&A deals? Share your experiences! #mergersandacquisitions #valuation

In a merger, the word “synergy” is often used to justify the deal.  In large enterprises, that synergy usually slows down at the data layer. When two organisations combine, the Board expects a unified view of customers, margins, supply chains, and risk exposure.  What they often inherit instead is a fragmented estate: multiple Snowflake environments, parallel ERP systems, legacy SQL Servers still running critical workloads, and no shared definition of basic metrics. This fragmentation is not an IT inconvenience. It is a structural drag on EBITDA. Finance teams spend months reconciling numbers instead of integrating operations.  Procurement savings remain theoretical because spend data cannot be harmonised.  Cross-sell strategies underperform because customer records do not align.  Leadership debates whose dashboard is “correct” instead of focusing on growth. It also creates 𝐀𝐈 𝐩𝐚𝐫𝐚𝐥𝐲𝐬𝐢𝐬. Enterprises talk about Copilots, GenAI layers, and agentic automation.  But you cannot deploy intelligent workflows on top of contradictory data logic.  If “Revenue” or “Margin” means something different across business units, automation only scales inconsistency. Post-merger value realisation requires a shift from moving data to governing logic. That begins with defining a shared semantic layer before merging a single table.  1. Agree on enterprise-wide definitions.  2. Assign domain accountability.  3. Rationalise overlapping platforms.  4. Decommission legacy debt rather than stacking new cloud costs on top of old architecture. True cost synergy comes from building a disciplined, scalable data foundation that supports unified reporting, controlled cloud economics, and AI readiness. Modernization in this context is about ensuring the combined enterprise operates on one coherent data engine, so the merger becomes a multiplier of value. #MergersAndAcquisitions #DataStrategy #EnterpriseAI #DigitalTransformation #DataGovernance #BusinessStrategy

𝗕𝘂𝘆𝗲𝗿 𝗕𝗲𝘄𝗮𝗿𝗲: 𝗞𝗲𝘆 𝗖𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀 𝗪𝗵𝗲𝗻 𝗔𝗰𝗾𝘂𝗶𝗿𝗶𝗻𝗴 𝗮 𝗠𝗲𝗱𝗶𝗰𝗮𝗹 𝗖𝗮𝗻𝗻𝗮𝗯𝗶𝘀 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 The #medicalcannabis sector presents significant opportunities, but buyers must approach acquisitions with a keen eye on the company's financial structure. The presence of debt, secured convertible loan notes (CLNs), & the mix of equity investors can introduce complexities that impact the long-term value and success of the investment. Understanding the Capital Structure When evaluating a potential acquisition, it’s essential to thoroughly assess the company's capital structure. A business heavily weighted with debt, including CLNs & debentures, may pose substantial risks. CLNs, in particular, can convert into equity, leading to significant dilution and potential shifts in ownership control. The terms of these conversions, such as discounts & valuation caps, can greatly influence the company’s future valuation & the buyer’s stake. The Impact of Debentures Debentures add another layer of financial obligation that must be carefully scrutinised. Secured debentures, which are backed by company assets, often take priority in repayment & can pose risks if these assets are critical to ongoing operations. Additionally, the timing of debenture maturities & the potential for early redemption clauses can affect cash flow & financial planning post-acquisition. Strategic & Valuation Implications Buyers must be aware that a capital structure dominated by CLNs and debentures might necessitate renegotiation of terms to stabilise the business. This could involve converting debt to equity or extending maturity dates to align with long-term growth strategies. Without such measures, the buyer might face unexpected financial burdens, including large payouts or refinancing needs, shortly after closing the deal. Moreover, the potential dilution from CLN conversions can result in a less favourable equity position for the buyer, affecting control & governance. It’s crucial to understand how these conversions will impact the overall ownership structure and prepare to manage these transitions effectively. Due Diligence is Key Given the complexities introduced by debt and CLNs, buyers should conduct rigorous due diligence to uncover any hidden liabilities, understand the full scope of financial obligations, & look for any undeclared debt, local or overseas. Adjusting the purchase price to account for these risks, or negotiating contingent considerations, can help mitigate potential downsides. In a market as dynamic as medical cannabis, the capital structure of the business you’re acquiring can be a double-edged sword. While the right acquisition can offer tremendous growth opportunities, failing to account for the intricacies of debt, CLNs, and equity can lead to significant challenges. Proceed with caution, & ensure that your strategy considers all the moving parts within the company’s financial architecture.

3 major MASH acquisitions in under a year. Roche, GSK, now Novo. Combined value over $9B. The market's sending a clear signal: MASH has moved from speculative to strategic necessity. Here's the competitive dynamic playing out: Novo owns GLP-1s. Wegovy and Ozempic generate tens of billions annually. MASH frequently stems from obesity. Acquiring Akero Therapeutics efruxifermin gives them both ends of the treatment spectrum. They can address the obesity AND the downstream liver damage. No one else has that combination. Roche paid $3.5B for 89Bio's pegozafermin last month. Similar mechanism to efruxifermin (FGF21 analog). They're betting on a parallel path to the same market. The clinical data showed comparable efficacy, so Roche bought its way into the race rather than starting 5 years behind. GSK grabbed Boston Pharmaceuticals experimental MASH drug for $1.2B upfront earlier this year. Different mechanism (THR-β agonist), potentially complementary to FGF21 approaches. They're hedging on mechanism diversity. What this tells us: The big pharma companies with deep metabolic disease franchises have decided MASH can't be ignored anymore. The patient population is massive (6-8% globally), growing with obesity rates, and there's almost no effective treatment currently available. The companies that waited are now paying premiums to catch up. Novo Nordisk's 16% premium looks reasonable until you factor in the 42% run-up from acquisition speculation. Roche paid a 127% premium for 89bio. GSK went straight to a $1.2B upfront payment before the asset even hit meaningful clinical milestones. Early movers got better deals. Late movers are paying for speed. The next 3-5 years will determine which mechanisms actually work in MASH. Multiple programs have failed spectacularly. The ones that succeed will define a $10B+ market. The ones that fail will write off billions in acquisition costs. But here's what's interesting: None of these companies could afford NOT to play. If MASH programs succeed and you're not in the game, you've ceded an entire treatment category to competitors. The cost of missing this market is higher than the cost of buying in. We're watching portfolio strategy play out in real time. Companies aren't just buying drugs. They're buying optionality on a market that might explode or might collapse, and they've decided the risk of missing it is worse than the cost of entry. What do you think drives the better ROI here - mechanism diversity or doubling down on proven approaches like FGF21? #Biotech #Pharma #Strategy #MASH #M&A

The Goldman Sachs Sixth Sense… There’s a reason why, over my ten years at Goldman, I rarely chased private company mergers: time is our scarcest asset, and the odds of closing rarely justified the lure of potential fees. Beyond a decade of grueling hours, always-on service, and relentless team-first mantras, you develop a few things. Deep pattern recognition, and some well-earned, fact-based biases among them. One sticks out today: private-to-private company mergers are brutally hard. But you wouldn’t know it from the volume of calls I used to get. “Scott! Just had an incredible dinner with [company]—we’re talking merger. We’re going to crush it!” My answer never changed: “Amazing. Align on governance and valuation, then call me back.” The phone never rang. → In Venture 4.0, consolidation is back in focus. As the strategic acquirers remain on the sidelines, the PE squads are sharpening their knives, the mega-VCs are raising dedicated rollup funds, and the speculative chatter has picked up. → When I say consolidations, I'm not talking about "soft landings" – those face-saving arrangements that are just a notch above bankruptcy. I'm talking about opportunistic mergers where 1+1=3. → These private-to-private mergers are exceptionally rare. The overwhelming majority of transactions valued over $500M involve a public company or private equity buyer; private mergers historically represent only 11% of transactions.   → Why is the private company consolidation so hard? While each situation has its unique challenges, here’s my checklist of gating factors that should be addressed upfront before anyone gets too excited: 1. Leadership: Clarity. Who takes “the conn”? These questions, often a function of ego, can create insurmountable barriers. Dividing and conquering works, but only if documented early and specifically. 2. Valuation: Relative. Focus on your share of the pie, not its absolute size - it's the only thing in your control. Avoid the trap of death by a thousand adjustments. KISS and win together. 3. Stakeholders: Complex. Understand the waterfall, the various rights and triggers. Identify and vet with critical decision makers early. Get in front of the most important people and issues. 4. Assumptions: Be brutal. Model all you want, then slash your assumptions in half. Integration needs chainsaws, not scalpels. Be conservative - wrong in that direction means upside. Ensure you have the talent and stomach for the job. When these harsh realities hit, you may need to revisit of item number one… → Lastly, as VCs navigate Venture 4.0, we can't just apply this lens to our portfolio companies. Perhaps we turn it on ourselves. The inevitable culling of the 3,000+ venture firms demands that we confront the same hard questions we pose to founders: if, how, and when to strategically consolidate. Can we successfully navigate our version of these critical questions? I wouldn’t count on a banker taking on that assignment! 🙂

𝗠𝗼𝘀𝘁 𝗠&𝗔 𝗱𝗲𝗮𝗹𝘀 𝗱𝗼𝗻’𝘁 𝗳𝗮𝗶𝗹 𝗮𝘁 𝘁𝗵𝗲 𝗻𝗲𝗴𝗼𝘁𝗶𝗮𝘁𝗶𝗻𝗴 𝘁𝗮𝗯𝗹e. 𝗧𝗵𝗲𝘆 𝗳𝗮𝗶𝗹 𝗶𝗻 𝘁𝗵𝗲 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻. In middle-market acquisitions, due diligence often misses: 🔸 Inflated working capital 🔸 Hidden tax exposures 🔸 Fragile Excel-driven systems 🔸 Understated liabilities These gaps can turn a “great deal” into an integration nightmare. That’s where I come in. As an 𝗶𝗻𝘁𝗲𝗿𝗶𝗺 𝗰𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗲𝗿 𝘄𝗶𝘁𝗵 𝗺𝘂𝗹𝘁𝗶𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗮𝗻𝗱 𝗽𝗿𝗶𝘃𝗮𝘁𝗲 𝗲𝗾𝘂𝗶𝘁𝘆 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲, I step in post-close to: ✔️ Stabilize cash and working capital ✔️ Align accounting policies with GAAP/IFRS ✔️ Mitigate tax and liability risks ✔️ Upgrade systems and controls for growth I just published an article breaking down t𝗵𝗲 𝗺𝗼𝘀𝘁 𝗰𝗼𝗺𝗺𝗼𝗻 𝗳𝗶𝗻𝗮𝗻𝗰𝗶𝗮𝗹 𝗯𝗹𝗶𝗻𝗱 𝘀𝗽𝗼𝘁𝘀 𝗶𝗻 𝗱𝘂𝗲 𝗱𝗶𝗹𝗶𝗴𝗲𝗻𝗰𝗲, 𝗮𝗻𝗱 𝗺𝘆 𝗽𝗹𝗮𝘆𝗯𝗼𝗼𝗸 𝗳𝗼𝗿 𝗳𝗶𝘅𝗶𝗻𝗴 𝘁𝗵𝗲𝗺. 👉 Contact me if you want a 𝘀𝗲𝗮𝘀𝗼𝗻𝗲𝗱 𝗰𝗼𝗻𝘁𝗿𝗼𝗹𝗹𝗲𝗿 𝘄𝗶𝘁𝗵 𝗮𝗰𝗾𝘂𝗶𝘀𝗶𝘁𝗶𝗼𝗻 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 to protect and grow your investment. #MergersAndAcquisitions #PrivateEquity #CFO #FinancialDueDiligence #AcquisitionIntegration

The $2.7 billion acquisition of Commonwealth by LPL Financial is more than just about scale. While it creates a $2 trillion giant, the integration of two firms with different cultures and technologies presents significant hurdles. Commonwealth advisors value their "small, boutique culture"; the success hinges on LPL truly adapting its model and ensuring a smooth platform conversion expected in mid-2026. Key considerations: 1️⃣ Integration Challenges: Maintaining advisor satisfaction and retention post-merger is critical but not guaranteed. Commonwealth advisors will closely watch the back-office experience for their clients. 2️⃣ Technology Convergence Risks: Integrating LPL and Commonwealth's tech platforms poses risks of complexity and disruptions, potentially impacting advisor productivity and client service. 3️⃣ Strategic Priorities and Costs: The all-cash deal and stock sale raise questions about capital allocation and if integration efforts will divert resources from other strategic goals, especially considering Commonwealth's recent $93 million SEC penalty. 4️⃣ Ecosystem Impact: This consolidation will pressure smaller firms and may spur further consolidation or opportunities for niche players. The long-term impact of this landmark deal depends on successful integration, technology convergence, strategic focus, and the broader competitive response, not just the sheer size of the merged entity. #wealthmanagement #financialadvisors #brokerdealer #mergersandacquisitions #LPL #Commonwealth #wealthtech #financialplanning

𝐂𝐚𝐬𝐡 𝐈𝐬 𝐊𝐢𝐧𝐠: 𝐖𝐨𝐫𝐤𝐢𝐧𝐠 𝐂𝐚𝐩𝐢𝐭𝐚𝐥 𝐚𝐬 𝐭𝐡𝐞 𝐁𝐚𝐫𝐨𝐦𝐞𝐭𝐞𝐫 𝐨𝐟 𝐈𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 In my years advising on cross-border M&A, one constant lesson has been: you don’t need to wait for an exit to know if an integration is working. Just look at working capital. It’s the real-time barometer of integration health. Research shows that 𝐮𝐩 𝐭𝐨 25% 𝐨𝐟 𝐟𝐚𝐢𝐥𝐮𝐫𝐞 𝐢𝐧 𝐦𝐢𝐝𝐜𝐚𝐩 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐜𝐨𝐦𝐞𝐬 𝐟𝐫𝐨𝐦 𝐩𝐨𝐨𝐫 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐜𝐚𝐩𝐢𝐭𝐚𝐥 𝐦𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭 (PwC, 2023). In the first 100 days, misaligned processes can trap millions in receivables, payables, or inventory. Liquidity, not EBITDA multiples, keeps integrations alive. From my experience, three dimensions matter most: - 𝐑𝐞𝐜𝐞𝐢𝐯𝐚𝐛𝐥𝐞𝐬 𝐝𝐢𝐬𝐜𝐢𝐩𝐥𝐢𝐧𝐞: Standardizing DSO across regions avoids cash stuck in silos. - 𝐏𝐚𝐲𝐚𝐛𝐥𝐞𝐬 𝐚𝐥𝐢𝐠𝐧𝐦𝐞𝐧𝐭: Harmonized terms prevent suppliers from exploiting inconsistent policies. - 𝐈𝐧𝐯𝐞𝐧𝐭𝐨𝐫𝐲 𝐭𝐮𝐫𝐧𝐬: Without unified planning, excess stock becomes a silent drain. A strong example is Symrise AG, the German fragrance and flavor mid-cap. When they integrated several European acquisitions, they streamlined AR/AP and inventory turns through coordinated TP and supply chain policies. That discipline unlocked hidden cash flow and accelerated value capture. Cash is king, but in integration, it’s also a compass. If working capital KPIs improve month by month, value creation is on track. If not, it’s a red flag. If you’re preparing a deal in 2025 or 2026, I’d be glad to share a working capital checklist I use to track integration health in real time. #PrivateEquity #WorkingCapital #CashFlow #ValueCreation #PostMergerIntegration #Synergies #EuropeanMidcaps #StrategyExecution #CFO #GlobalPMIPartners #Strategy

Big pharma dropped $6.6B on in-vivo CAR-T startups in under a year. But this only a small niche compared to the entire Biotech M&A space. For In Vivo cell engineering From March until last October: Bristol Myers Squibb → Orbital Therapeutics ($1.5B) Gilead/Kite → Interius ($350M) + Pregene ($1.64B) AbbVie → Capstan Therapeutics ($2.1B) AstraZeneca → EsoBiotec ($1B) So why Big Pharma prefers to buy instead of build own R&D programs? Three reasons small biotechs win at innovation: #1 Cost advantage Big pharma's overhead is massive. Executive layers, complex infrastructure, global operations. A fully loaded FTE at J&J costs far more than at a 50-employee biotech. Small companies run lean and hungry. #2 Laser focus Big pharma kills programs at the first sign of trouble. "Fail early" sounds smart, but most successful drugs survived near-death moments. Small biotechs can't afford to quit. They only have 1-2 programs. That desperation breeds breakthroughs. #3 Organizational alignment Ever heard of the organizational iceberg? In large companies, only 4% of problems reach senior management. In a startup, the CEO knows everything happening at the bench. No layers. No information loss. Everyone's aligned on the mission. As a curious note you can read about the critical operational number defined by Dunbar (link below). In 2024, only 23 of 55 FDA approvals came from companies with $3B+ in sales. Small biotechs are outinnovating giants. Big pharma just figured this out. Why fund 10 risky programs internally when you can let the market fund 100 and cherry-pick the winners? It's not laziness. It's strategy. What's your take?